PE20171337A1 - Inhibidores selectivos de bace1 - Google Patents
Inhibidores selectivos de bace1Info
- Publication number
- PE20171337A1 PE20171337A1 PE2017001256A PE2017001256A PE20171337A1 PE 20171337 A1 PE20171337 A1 PE 20171337A1 PE 2017001256 A PE2017001256 A PE 2017001256A PE 2017001256 A PE2017001256 A PE 2017001256A PE 20171337 A1 PE20171337 A1 PE 20171337A1
- Authority
- PE
- Peru
- Prior art keywords
- tetrahydrofuro
- thiazin
- difluoroethyl
- triazol
- pyrazine
- Prior art date
Links
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- XANIWDNIBGABPW-GQNMWPQZSA-N N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(1,2,4-triazol-1-yl)pyrazine-2-carboxamide Chemical compound NC=1SC[C@H]2[C@@](N=1)(CO[C@@H]2C(C)(F)F)C=1C=C(C=CC=1F)NC(=O)C1=NC=C(N=C1)N1N=CN=C1 XANIWDNIBGABPW-GQNMWPQZSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 1
- 102100021257 Beta-secretase 1 Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
Abstract
Se refiere a un compuesto de formula II o a su sal farmaceuticamente aceptable, donde R es metilo, etilo o ciclopropilo. Son compuestos preferidos: N-[3-[(4aS, 5S, 7aS)-2-amino-5-(1,1-difluoroetil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-(1,2,4-triazol-1-il)pirazina-2-carboxamida; malonato de N-[3-[(4aS, 5S, 7aS)-2-amino-5-(1,1-difluoroetil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-(1,2,4-triazol-1-il)pirazina-2-carboxamida, entre otros. Tambien se refiere a una composicion farmaceutica y a un procedimiento de obtencion. Dichos compuestos son inhibidores selectivos de la enzima de escision de la proteina precursora amiloide de beta-sitio-1 (BACE1), siendo utiles en el tratamiento de la enfermedad de Alzheimer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562119391P | 2015-02-23 | 2015-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20171337A1 true PE20171337A1 (es) | 2017-09-13 |
Family
ID=55442893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017001256A PE20171337A1 (es) | 2015-02-23 | 2016-02-17 | Inhibidores selectivos de bace1 |
Country Status (27)
Country | Link |
---|---|
US (1) | US9522923B2 (es) |
EP (1) | EP3262051B1 (es) |
JP (1) | JP6111001B1 (es) |
KR (1) | KR101945139B1 (es) |
CN (1) | CN107257801B (es) |
AR (1) | AR103680A1 (es) |
AU (1) | AU2016223072B2 (es) |
BR (1) | BR112017013936A2 (es) |
CA (1) | CA2972098A1 (es) |
CL (1) | CL2017002090A1 (es) |
CO (1) | CO2017008382A2 (es) |
CR (1) | CR20170315A (es) |
DO (1) | DOP2017000178A (es) |
EA (1) | EA031546B1 (es) |
EC (1) | ECSP17054980A (es) |
GT (1) | GT201700185A (es) |
IL (1) | IL252969A0 (es) |
MX (1) | MX367940B (es) |
NZ (1) | NZ732940A (es) |
PE (1) | PE20171337A1 (es) |
PH (1) | PH12017501523A1 (es) |
SG (1) | SG11201705764SA (es) |
SI (1) | SI3262051T1 (es) |
TN (1) | TN2017000355A1 (es) |
TW (1) | TWI627177B (es) |
WO (1) | WO2016137788A1 (es) |
ZA (1) | ZA201704293B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
EP3271356B1 (en) | 2015-03-19 | 2019-10-16 | Eli Lilly and Company | Selective bace1 inhibitors |
AR104241A1 (es) | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EA201892216A1 (ru) | 2016-03-31 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
DK3436435T3 (da) | 2016-03-31 | 2021-08-09 | Janssen Pharmaceuticals Inc | Substituerede indolderivater som inhibitorer af replikation af denguevirus |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
SG11201808237UA (en) | 2016-04-01 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indole compound derivatives as dengue viral replication inhibitors |
WO2018034977A1 (en) * | 2016-08-18 | 2018-02-22 | Eli Lilly And Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EA201992782A1 (ru) | 2017-05-22 | 2020-03-24 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
AU2018274101C1 (en) | 2017-05-22 | 2022-09-15 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008543849A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
EP2233474B1 (en) * | 2008-01-18 | 2015-08-05 | Eisai R&D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
CN102119161B (zh) | 2008-06-13 | 2015-07-08 | 盐野义制药株式会社 | 具有β分泌酶抑制作用的含硫杂环衍生物 |
CA2738150A1 (en) | 2008-09-30 | 2010-04-08 | Eisai R&D Management Co., Ltd. | Novel fused aminodihydrothiazine derivative |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101139D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101140D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
WO2014015125A1 (en) | 2012-07-19 | 2014-01-23 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivative salts and uses thereof |
GB201212816D0 (en) * | 2012-07-19 | 2012-09-05 | Eisai Ltd | Novel compounds |
TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
TWI639607B (zh) * | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Bace抑制劑 |
AR104241A1 (es) * | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
-
2016
- 2016-02-12 AR ARP160100396A patent/AR103680A1/es unknown
- 2016-02-15 TW TW105104352A patent/TWI627177B/zh not_active IP Right Cessation
- 2016-02-17 AU AU2016223072A patent/AU2016223072B2/en not_active Ceased
- 2016-02-17 BR BR112017013936A patent/BR112017013936A2/pt not_active Application Discontinuation
- 2016-02-17 TN TNP/2017/000355A patent/TN2017000355A1/en unknown
- 2016-02-17 US US15/045,305 patent/US9522923B2/en not_active Expired - Fee Related
- 2016-02-17 NZ NZ732940A patent/NZ732940A/en not_active IP Right Cessation
- 2016-02-17 EP EP16706731.3A patent/EP3262051B1/en active Active
- 2016-02-17 EA EA201791684A patent/EA031546B1/ru not_active IP Right Cessation
- 2016-02-17 WO PCT/US2016/018160 patent/WO2016137788A1/en active Application Filing
- 2016-02-17 CN CN201680011583.5A patent/CN107257801B/zh not_active Expired - Fee Related
- 2016-02-17 SI SI201630428T patent/SI3262051T1/sl unknown
- 2016-02-17 PE PE2017001256A patent/PE20171337A1/es unknown
- 2016-02-17 MX MX2017010861A patent/MX367940B/es active IP Right Grant
- 2016-02-17 SG SG11201705764SA patent/SG11201705764SA/en unknown
- 2016-02-17 CA CA2972098A patent/CA2972098A1/en not_active Abandoned
- 2016-02-17 KR KR1020177023007A patent/KR101945139B1/ko active IP Right Grant
- 2016-02-17 CR CR20170315A patent/CR20170315A/es unknown
- 2016-02-17 JP JP2016558188A patent/JP6111001B1/ja not_active Expired - Fee Related
-
2017
- 2017-06-18 IL IL252969A patent/IL252969A0/en unknown
- 2017-06-23 ZA ZA2017/04293A patent/ZA201704293B/en unknown
- 2017-07-31 DO DO2017000178A patent/DOP2017000178A/es unknown
- 2017-08-01 GT GT201700185A patent/GT201700185A/es unknown
- 2017-08-16 CO CONC2017/0008382A patent/CO2017008382A2/es unknown
- 2017-08-16 CL CL2017002090A patent/CL2017002090A1/es unknown
- 2017-08-22 EC ECIEPI201754980A patent/ECSP17054980A/es unknown
- 2017-08-23 PH PH12017501523A patent/PH12017501523A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20171337A1 (es) | Inhibidores selectivos de bace1 | |
CY1121433T1 (el) | Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4 | |
NZ745957A (en) | Heterocyclic amides useful as protein modulators | |
EA201600622A1 (ru) | Бициклические анелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4 | |
PE20170520A1 (es) | Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
PE20190761A1 (es) | Inhibidores de procesos metabolicos celulares | |
PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
PE20141182A1 (es) | Derivados fusionados de aminodihidrotiazina | |
EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
EA201890338A1 (ru) | Оксадиазольные производные, пригодные в качестве ингибиторов hdac | |
EA201792254A1 (ru) | Малеатные соли ингибитора braf киназы, кристаллические формы, способы их получения и применения | |
PE20170464A1 (es) | Terapia de combinacion de alzheimer usando un anticuerpo monoclonal abeta anti-n3pglu mas un inhibidor de bace | |
EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
EA201700504A1 (ru) | 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение | |
PE20142244A1 (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina | |
MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
EA201891609A1 (ru) | Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
EA201890524A1 (ru) | (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака | |
EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта |